Literature DB >> 10546021

Soluble intercellular adhesion molecule, vascular cell adhesion molecule, and impaired microvascular reactivity are early markers of vasculopathy in type 2 diabetic individuals without microalbuminuria.

S C Lim1, A E Caballero, P Smakowski, F W LoGerfo, E S Horton, A Veves.   

Abstract

OBJECTIVE: Using von Willebrand Factor (vWF) as a marker of endothelial function, previous studies have shown that the development of microalbuminuria is associated with the onset of endothelial dysfunction in individuals with type 2 diabetes. We tested the hypothesis that endothelial dysfunction is already evident in normoalbuminuric individuals with type 2 diabetes. RESEARCH DESIGN AND METHODS: We used laser Doppler imaging scanning to measure vasodilation in the forearm skin in response to iontophoresis of 1% acetylcholine (endothelium-dependent) and 1% sodium nitroprusside (endothelium-independent). Multiple indicators of endothelial function--soluble intercellular adhesion molecule (sICAM), soluble vascular cell adhesion molecule (sVCAM), vWF, and microvascular reactivity--were measured in 20 healthy control subjects, 45 normoalbuminuric (urinary albumin/creatinine ratio < 30 micrograms/mg) individuals with type 2 diabetes, and 14 microalbuminuric (urinary albumin/creatinine ratio between 30 and 300 micrograms/mg) individuals with type 2 diabetes.
RESULTS: Serum sICAM and sVCAM levels were elevated in the normoalbuminuric (305 +/- 120, 851 +/- 284 ng/ml) and microalbuminuric (300 +/- 89, 845 +/- 252 ng/ml) individuals with diabetes when compared with the healthy control subjects (213 +/- 58, 661 +/- 176 ng/ml) (P < 0.01). Furthermore, the microvascular endothelium-dependent and -independent vasodilation was reduced in the normoalbuminuric (76 +/- 44, 70 +/- 33) (percent increase in perfusion over baseline) and microalbuminuric (74 +/- 41, 73 +/- 28) individuals with diabetes compared with healthy control subjects (126 +/- 67, 120 +/- 47) (P < 0.05). In contrast, plasma vWF was elevated only in the microalbuminuric individuals with diabetes (129 +/- 35%) compared with the normoalbuminuric individuals with diabetes (110 +/- 34) and healthy control subjects (111.3 +/- 39) (P < 0.05). On stepwise multivariate analysis, fasting blood glucose was the most important contributing factor to the variation in microvascular reactivity and sVCAM, whereas insulin resistance (by homeostasis model assessment) was the most important contributing factor to the variation in sICAM. Addition of all clinical and biochemical measures explained only 15-22% of the variation in sICAM, sVCAM, and microvascular reactivity.
CONCLUSIONS: Multiple markers of endothelial dysfunction were evident in normoalbuminuric individuals with type 2 diabetes. The pathogenic process of vasculopathy in type 2 diabetes occurs early and may be operative before the development of microalbuminuria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10546021     DOI: 10.2337/diacare.22.11.1865

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  26 in total

Review 1.  Endothelial dysfunction, inflammation, and insulin resistance: a focus on subjects at risk for type 2 diabetes.

Authors:  A Enrique Caballero
Journal:  Curr Diab Rep       Date:  2004-08       Impact factor: 4.810

Review 2.  Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy.

Authors:  Richard J Woodman; Gerard T Chew; Gerald F Watts
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Dynamic evaluation of renal resistive index in normoalbuminuric patients with newly diagnosed hypertension or type 2 diabetes.

Authors:  R M Bruno; E Daghini; L Landini; D Versari; A Salvati; E Santini; I Di Paco; A Magagna; S Taddei; L Ghiadoni; A Solini
Journal:  Diabetologia       Date:  2011-04-16       Impact factor: 10.122

4.  Glycated peptides are associated with proximal tubule dysfunction in type 2 diabetes mellitus.

Authors:  Ligia Petrica; Adrian Vlad; Gheorghe Gluhovschi; Alina Zamfir; Cristina Popescu; Florica Gadalean; Victor Dumitrascu; Daliborca Vlad; Roxana Popescu; Silvia Velciov; Cristina Gluhovschi; Flaviu Bob; Oana Milas; Sorin Ursoniu
Journal:  Int J Clin Exp Med       Date:  2015-02-15

5.  Oral administration of α-ketoglutarate enhances nitric oxide synthesis by endothelial cells and whole-body insulin sensitivity in diet-induced obese rats.

Authors:  Carmen D Tekwe; Kang Yao; Jian Lei; Xilong Li; Anand Gupta; Yuanyuan Luan; Cynthia J Meininger; Fuller W Bazer; Guoyao Wu
Journal:  Exp Biol Med (Maywood)       Date:  2019-07-29

Review 6.  Assessing Microvascular Function in Humans from a Chronic Disease Perspective.

Authors:  Alfons J H M Houben; Remy J H Martens; Coen D A Stehouwer
Journal:  J Am Soc Nephrol       Date:  2017-09-13       Impact factor: 10.121

7.  Quantitative trait locus analysis of circulating adhesion molecules in hyperlipidemic apolipoprotein E-deficient mice.

Authors:  Zuobiao Yuan; Zhiguang Su; Toru Miyoshi; Jessica S Rowlan; Weibin Shi
Journal:  Mol Genet Genomics       Date:  2008-08-13       Impact factor: 3.291

8.  Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Authors:  Wen-Hao Tang; Fu-Huang Lin; Chien-Hsing Lee; Feng-Chih Kuo; Chang-Hsun Hsieh; Fone-Ching Hsiao; Yi-Jen Hung
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

9.  Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones.

Authors:  Kuo-Chien Tsao; Tsu-Lan Wu; Pi-Yueh Chang; Chien-Feng Sun; Lily L Wu; James T Wu
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 10.  Vascular smooth muscle function in type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  David Montero; Guillaume Walther; Antonia Pérez-Martin; Nestor Vicente-Salar; Enrique Roche; Agnès Vinet
Journal:  Diabetologia       Date:  2013-07-18       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.